INVO Bioscience (NASDAQ:INVO) is a medical technology company focused on advancing fertility treatments through innovative intravaginal culture solutions. The company’s flagship product, INVOcell®, is a proprietary device designed to facilitate in vitro fertilization (IVF) by allowing fertilization and early embryo development to occur within a patient’s vaginal cavity. By integrating key steps of the IVF process into a single device, INVOcell® aims to simplify laboratory requirements, potentially reduce procedural costs, and offer a patient-centric approach to assisted reproductive technology.
INVO Bioscience’s primary business activities encompass product development, regulatory approval, and commercialization of its INVOcell® system. The company collaborates with fertility clinics and healthcare providers to integrate its intravaginal culture solution into existing IVF protocols. In addition to device manufacturing, INVO Bioscience provides specialized training and support services, ensuring clinicians are fully equipped to adopt and optimize intravaginal culture procedures in their practices.
Since its founding in 2007, INVO Bioscience has pursued a strategy of global expansion through strategic partnerships and licensing agreements. Headquartered in Beverly, Massachusetts, the company has extended its reach into North America, Latin America, Europe, Asia and the Middle East. These collaborations enable local fertility centers to offer INVOcell® as an alternative to conventional laboratory-based IVF, broadening access to fertility care in diverse healthcare markets.
The company’s leadership team combines deep expertise in reproductive medicine, regulatory affairs and commercial operations. Founder and Chairman Dr. Jerome F. Sher, a pioneer in minimally invasive reproductive technologies, guides INVO Bioscience’s scientific vision. President and CEO Javier Suarez oversees global strategy, business development and operational execution. Under this management structure, INVO Bioscience continues to advance research, secure regulatory clearances and strengthen its position as a leader in patient-focused fertility solutions.
